© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Combining two experimental oral hepatitis C drugs from Bristol-Myers Squibb (BMS)--daclatasvir, a once-daily NS5a inhibitor, and...
Hepatitis C virus (HCV) protease inhibitors are not cost-effective for first-time treatment takers with HCV genotype 1 and the IL-28B CC genot...
People with liver cirrhosis may benefit from daily therapy with a blood thinner to prevent portal vein thrombosis (PVT)
Boehringer Ingelheim has its eyes set on interferon-free treatment for genotype 1 hepatitis C virus (HCV) infection. The treatment combines tw...
Silymarin, an extract of milk thistle (Carduus marianus), had no benefit on levels of the liver enzyme alanine aminotransferase (ALT) in peopl...
Alisporivir, a once-daily drug being developed by Novartis at the forefront of a new class of hepatitis C virus (HCV) compounds known as cyclo...
Adding Janssen Therapeutics’ TMC435, a once-daily experimental hepatitis C virus (HCV) protease inhibitor, to pegylated interferon and ribavir...
Testing all U.S. baby boomers for hepatitis C virus (HCV) infection would help identify more than 800,000 people living with the virus.
Data continue to mount, indicating that not only can hepatitis B virus (HBV) medications work for many years, but they can also help reverse l...
Chronic hepatitis C virus (HCV) infection is associated with more deaths than HIV infection, according to sobering new data presented by...
There doesn?t appear to be an advantage to combining Baraclude (entecavir) with Viread (Tenofovir) to manage chronic hepatitis B virus (HBV) i...
Miravirsen, a novel injectable drug targeting a ’microRNA’ known as miR-122 responsible for the accumulation of hepatitis C virus (HCV) in the...
Roughly 70 percent of people living with HIV and hepatitis C virus (HCV) coinfection have undetectable HCV viral loads after 24 weeks of treat...
Combining Pharmasset?s once-daily experimental nucleotide analog PSI-7977 with pegylated interferon and ribavirin cured 91 percent of 47 peopl...
A twelve-week course of Pharmasset?s once-daily experimental nucleotide analog PSI-7977, combined with ribavirin, cured 10 of 10 people living...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.